Cart
sales@molnova.com
AVP-13358
CAS No. 459805-03-9
AVP-13358( —— )
Catalog No. M34514 CAS No. 459805-03-9
AVP-13358 is a CD23 antagonist (immunoglobulin ε-Fc receptor antagonist), an immunoglobulin E inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 472 | In Stock |
|
| 10MG | 644 | In Stock |
|
| 25MG | 905 | In Stock |
|
| 50MG | 1097 | In Stock |
|
| 100MG | 1395 | In Stock |
|
| 200MG | 1823 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAVP-13358
-
NoteResearch use only, not for human use.
-
Brief DescriptionAVP-13358 is a CD23 antagonist (immunoglobulin ε-Fc receptor antagonist), an immunoglobulin E inhibitor.
-
DescriptionAVP-13358 is a CD23 antagonist (immunoglobulin ε-Fc receptor antagonist), an immunoglobulin E inhibitor. AVP-13358 has potent activity against IgE, cytokines and CD23 and is used in the treatment of immune system disorders, infections and otolaryngological disorders.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number459805-03-9
-
Formula Weight491.58
-
Molecular FormulaC30H29N5O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(NC1=CC=C(C=C1)C=2NC=3C(N2)=CC=C(C(NC4=CC=CC=N4)=O)C3)(=O)C56CC7CC(C5)CC(C6)C7
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
L-838417
L-838417 is a GABAA receptor subtype-selective benzodiazepine site-selective ligand and GABAA receptor-positive modulator.
-
IRG1-IN-1
IRG1-IN-1, an itaconic acid derivative, inhibits Immune Response Gene 1 (IRG1) activity and is suitable for cancer, inflammation, and autoimmune disease research.
-
BMS-P5 free base
BMS-P5 free base is a specific and orally active peptidylarginine deiminase 4 (PAD4) inhibitor.?BMS-P5 Blocks Formation of Neutrophil Extracellular Traps and Delays Progression of Multiple Myeloma.
